FibroGen Inc (NASDAQ: FGEN) Metrics That Matter Right Now

FibroGen Inc (NASDAQ:FGEN) shares, rose in value, with the stock price down by -31.94% to the previous day’s close as strong demand from buyers drove the stock to $1.47.

Actively observing the price movement in the last trading, the stock closed the session at $2.16. The value of beta (5-year monthly) was 0.66. Referring to stock’s 52-week performance, its high was $20.90, and the low was $0.33. On the whole, FGEN has fluctuated by -25.76% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


With the market capitalization of FibroGen Inc currently standing at about $145.19 million, investors are eagerly awaiting this quarter’s results, scheduled for May 06, 2024 – May 10, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.41, which is expected to increase to -$0.3 for fiscal year -$1.29 and then to about -$0.43 by fiscal year 2025. Data indicates that the EPS growth is expected to be 55.80% in 2025, while the next year’s EPS growth is forecast to be 66.70%.

Analysts have estimated the company’s revenue for the quarter at $36.45 million, with a low estimate of $31.89 million and a high estimate of $41 million. According to the average forecast, sales growth in current quarter could jump up 14.50%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $158.36 million, representing an increase of 7.20% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that FGEN’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a Hold.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of FGEN currently trading nearly -32.55% and -26.01% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.01, while the 7-day volatility ratio is showing 26.45% which for the 30-day chart, stands at 15.51%. Furthermore, FibroGen Inc (FGEN)’s beta value is 0.74, and its average true range (ATR) is 0.33.

A comparison of FibroGen Inc (FGEN) with its peers suggests the former has fared considerably weaker in the market. FGEN showed an intraday change of -31.94% in last session, and over the past year, it shrunk by -92.12%%.

Data on historical trading for FibroGen Inc (NASDAQ:FGEN) indicates that the trading volumes over the past 10 days have averaged 2.31 million and over the past 3 months, they’ve averaged 2.61 million. According to company’s latest data on outstanding shares, there are 98.77 million shares outstanding.

Nearly 7.02% of FibroGen Inc’s shares belong to company insiders and institutional investors own 71.23% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.53 million shares as on Mar 15, 2024, resulting in a short ratio of 3.12. According to the data, the short interest in FibroGen Inc (FGEN) stood at 5.60% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 7.21 million. The stock has risen by 65.86% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the FGEN stock heading into the next quarter.